Evidence
J Hepatol. 2023 Oct 23:S0168-8278(23)05182-6. doi: 10.1016/j.jhep.2023.10.015. Online ahead of print.
ABSTRACT
Non-alcoholic steatohepatitis (NASH) prevalence is increasing worldwide, causing a significant medical burden, but no approved therapeutics are currently available. NASH drug development requires histological analysis of liver biopsies by expert pathologists for trial enrollment and efficacy assessment, which can be hindered by multiple issues including sample heterogeneity, inter-reader and intra-reader variability, and ordinal scoring systems. Consequently, there is a high unmet need for accurate, reproducible, quantitative, and automated methods to assist pathologists with histological analysis to improve the precision around treatment and efficacy assessment. Digital pathology (DP) workflows in combination with artificial intelligence (AI) have been established in other areas of medicine and are being actively investigated in NASH to assist pathologists in the evaluation and scoring of NASH histology. DP/AI models can be used to automatically detect, localize, quantify, and score histological parameters and have the potential to reduce the impact of scoring variability in NASH clinical trials. This narrative review provides an overview of DP/AI tools in development for NASH, highlights key regulatory considerations, and discusses how these advances may impact the future of NASH clinical management and drug development. This should be a high priority in the NASH field, particularly to improve the development of safe and effective therapeutics.
PMID:37879461 | DOI:10.1016/j.jhep.2023.10.015
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
- Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing
- Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing
- The Role of CD4+T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
- Outcome prediction in metabolic dysfunction-associated steatotic liver disease using stain-free digital pathological assessment
- Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
- Reliability of an Expanded Non-alcoholic Steatohepatitis Grading and Staging System for Assessment of Disease Activity and Fibrosis
- Reliability of an Expanded Non-alcoholic Steatohepatitis Grading and Staging System for Assessment of Disease Activity and Fibrosis
- HIF-2α drives hepatic Kupffer cell death and proinflammatory recruited macrophage activation in nonalcoholic steatohepatitis
- Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future
- Will Precision Medicine Meet Digital Health? A Systematic Review of Pharmacogenomics Clinical Decision Support Systems Used in Clinical Practice
- Will Precision Medicine Meet Digital Health? A Systematic Review of Pharmacogenomics Clinical Decision Support Systems Used in Clinical Practice
- Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis
- Clinical-Grade Validation of an Autofluorescence Virtual Staining System with Human Experts and a Deep Learning System for Prostate Cancer
- Prescription digital therapeutics: An emerging treatment option for negative symptoms in schizophrenia
- Prescription digital therapeutics: An emerging treatment option for negative symptoms in schizophrenia
- Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis
- Assessment of Breast Pathology Reporting Needs and Development of Tumor Synoptic Templates in Sub-Saharan Africa
- Depletion of Activated Hepatic Stellate Cells and Capillarized Liver Sinusoidal Endothelial Cells Using a Rationally Designed Protein for Nonalcoholic Steatohepatitis and Alcoholic Hepatitis Treatment
- Danggui-Shaoyao-San protects against non-alcoholic steatohepatitis via modulation of hepatic APP protein, Lysosomal CTSB release, and NF-kappaB activation
- Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics
- Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology
- Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology
- Development of a multi-scanner facility for data acquisition for digital pathology artificial intelligence
- Advances in estimating plasma cells in bone marrow: A comprehensive method review
- Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017-2020
- Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National Health and Nutrition Examination Survey, 2017-2020
- Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
- Integrated serum metabolomics, 16S rRNA sequencing and bile acid profiling to reveal the potential mechanism of gentiopicroside against nonalcoholic steatohepatitis in lean mice
- CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
- A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice
- Visceral Fat Associated with Worsening of Recurrent Esophageal Varices in Alcoholic/Nonalcoholic Steatohepatitis-Related Liver Cirrhosis
- Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways
- Drug repurposing for cancer
- Drug repurposing for cancer
- Towards accurate and efficient diagnoses in nephropathology: An AI-based approach for assessing kidney transplant rejection
- A decision support system for the detection of cutaneous fungal infections using artificial intelligence
- Immunobiotic Bacteria Attenuate Hepatic Fibrosis through the Modulation of Gut Microbiota and the Activation of Aryl-Hydrocarbon Receptors Pathway in Non-Alcoholic Steatohepatitis Mice
- Digital Therapeutics in Hearing Healthcare: Evidence-Based Review
- Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding
- Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease
- Excretory/secretory antigens from Trichinella spiralis muscle larvae ameliorate HFD-induced non-alcoholic steatohepatitis via driving macrophage anti-inflammatory activity
- miR-33 deletion in hepatocytes attenuates NAFLD-NASH-HCC progression
- Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems
- Artificial Intelligence in Autoimmune Bullous Dermatoses
- Efficacy and safety of resmetirom among patients with non-alcoholic steatohepatitis: a systematic review and meta-analysis
- Development, validation and implementation of an augmented multi-well, multi-target quantitative PCR-HPV genotyping analysis through software automation, data science and artificial intelligence
- The Role of Telemedicine in Strabismus Assessment: A Narrative Review and Meta-Analysis
- The Role of Telemedicine in Strabismus Assessment: A Narrative Review and Meta-Analysis
- Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus
- Unravelling the diagnostic pathology and molecular biomarkers in lung cancer
- Artificial intelligence applications in gastroenterology: steps ahead
- Artificial intelligence applications in gastroenterology: steps ahead
- Artificial intelligence and machine learning for anaphylaxis algorithms
- Evaluation of AI-based Gleason grading algorithms "in the wild"
- Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin
- Decrease in UCP1 by sustained high lipid promotes NK cell necroptosis to exacerbate nonalcoholic liver fibrosis
- Navigating the future of health care with AI-driven digital therapeutics
- A Theory and Evidence-Based Artificial Intelligence-Driven Motivational Digital Assistant to Decrease Vaccine Hesitancy: Intervention Development and Validation
- Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
- Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
- Application of digital workflow and technologies in clinical paediatric dentistry: a scoping review
- Obstructive Sleep Apnea Syndrome Exacerbates NASH Progression via Selective Autophagy-Mediated Eepd1 Degradation
- Machine learning model for non-alcoholic steatohepatitis diagnosis based on ultrasound radiomics
Evidence Blueprint
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Artificial intelligence scoring of liver biopsies in a phase ii trial of semaglutide in non-alcoholic steatohepatitis
- Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials
- Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics
- NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review
- Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
- Identification and multicentric validation of soluble CDCP1 as a robust serological biomarker for risk stratification of NASH in obese Chinese
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- Artificial Intelligence in Digital Histopathology for predicting patient prognosis and treatment efficacy in breast cancer
- Deep learning-based assay for programmed death ligand 1 immunohistochemistry scoring in non-small cell lung carcinoma: Does it help pathologists score?
- Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing
- Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing
- Herpetrione, a New Type of PPARα Ligand as a Therapeutic Strategy Against Nonalcoholic Steatohepatitis
- A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL
- Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis
- PIT-EASY survey: validation of the European Pituitary Pathology Group proposal for reporting pituitary neuroendocrine tumors
- Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids
- 4,4-Diallyl curcumin bis(2,2-hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine-choline-deficient diet and Western diet mouse models
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- NAFLD and NASH: etiology, targets and emerging therapies
- Potent Efficacy of 3-Amino-4-hydroxy Benzoic Acid, a Small Molecule Having Anti-fibrotic Activity, in a Mouse Model of Non-alcoholic Steatohepatitis
- The Role of CD4+T Cells in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
- Outcome prediction in metabolic dysfunction-associated steatotic liver disease using stain-free digital pathological assessment
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Harnessing artificial intelligence for prostate cancer management
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- Correlation of alanine aminotransferase levels and a histological diagnosis of steatohepatitis with ultrasound-diagnosed metabolic-associated fatty liver disease in patients from a centre in Nigeria
- Pseudotargeted lipidomics analysis of scoparone on glycerophospholipid metabolism in non-alcoholic steatohepatitis mice by LC-MRM-MS
- A deep-learning-based model for assessment of autoimmune hepatitis from histology: AI(H)
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts
- Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review
- Dynamics of cellular plasticity in non-alcoholic steatohepatitis (NASH)
- Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies
- Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
- Assessment of Efficacy and Accuracy of Cervical Cytology Screening with Artificial Intelligence Assistive System
- Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis
- Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis
- Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease
- The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity
- The role of N6-methyladenosine in macrophage polarization: A novel treatment strategy for non-alcoholic steatohepatitis
- Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis
- Identification of pyroptosis-related gene signature in nonalcoholic steatohepatitis
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Investigating the tamoxifen/high-fat diet synergy: a promising paradigm for nonalcoholic steatohepatitis induction in a rat model
- Poly(ADP-ribose) polymerase (PARP)-targeted PET imaging in non-oncology application: a pilot study in preclinical models of nonalcoholic steatohepatitis
- Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium
- Reliability of an Expanded Non-alcoholic Steatohepatitis Grading and Staging System for Assessment of Disease Activity and Fibrosis
- Reliability of an Expanded Non-alcoholic Steatohepatitis Grading and Staging System for Assessment of Disease Activity and Fibrosis
- Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review
- Yanggan Jiangmei Formula alleviates hepatic inflammation and lipid accumulation in non-alcoholic steatohepatitis by inhibiting the NF-kappaB/NLRP3 signaling pathway
- Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Therapeutic management of metabolic dysfunction associated steatotic liver disease
- Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice
- HIF-2α drives hepatic Kupffer cell death and proinflammatory recruited macrophage activation in nonalcoholic steatohepatitis
- Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease
- Therapeutic efficacy of mitochondria-targeted esculetin in the improvement of NAFLD-NASH via modulating AMPK-SIRT1 axis
- Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future
- Will Precision Medicine Meet Digital Health? A Systematic Review of Pharmacogenomics Clinical Decision Support Systems Used in Clinical Practice
- Will Precision Medicine Meet Digital Health? A Systematic Review of Pharmacogenomics Clinical Decision Support Systems Used in Clinical Practice